International Clinical Trial: Efficacy and Safety of Withdrawing Ivarmacitinib or Conventional Synthetic DMARDs in Rheumatoid Arthritis Patients Achieving Low Disease Activity After Combination Therapy: A Prospective, Multicenter, Randomized Controlled Study

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119971) titled 'Efficacy and Safety of Withdrawing Ivarmacitinib or Conventional Synthetic DMARDs in Rheumatoid Arthritis Patients Achieving Low Disease Activity After Combination Therapy: A Prospective, Multicenter, Randomized Controlled Study' on March 6.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Hospital of China Medical University

Condition: Rheumatoid Arthritis

Intervention: Experimental group:Ivarmacitinib Monotherapy

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-03-31

Target Sample Size: Experimental group:52;Control Group:52;

Countries...